7 Bell Yard, London, WC2A 2JR
enquiries@norcliffe.capital
Supporting the Next Generation of
Supporting the Next Generation of
SUPPORTING THE NEXT GENERATION OF
Breakthrough Technologies
[rev_slider alias=”slider-1″][/rev_slider]
Breakthrough Technologies
Breakthrough Technologies
Our Investment Portfolio
Supporting the next generation of breakthrough technologies
SELECT, SUPPORT, SUCCEED
Providing direct investment in ground-breaking life science and technology companies.
With decades of combined business experience in the life science and technology sectors, Norcliffe Capital provides more than capital to support our investments. We use our experience and expertise to select UK based growth companies in our specialist sectors and support them throughout their commercial journey.
Norcliffe Capital offers investors the opportunity to directly invest in individual private companies in the life science and disruptive technology sectors. Our investments typically target a return of 3-10x investment over 4 to 7 years with the aim of realising each investment, perhaps by the sale of the company or a listing on a stock exchange, to generate a capital return.
Our investors have the opportunity to invest in the UK’s leading innovative investments via tax efficient schemes.
Depending on the level of investment, family offices can take a seat on the board, or you can rely on Norcliffe Capital to represent you and protect your interests.
We take exceptional care in the choice of our investments, only supporting those that meet our investment mandate.
We are supportive funding partners who work with you on improving operational performance, corporate governance, structure and strategy.
The Enterprise Investment Scheme
Encouraging investment into UK companies to support innovation and drive our economy forward.
Latest News
Latest news and updates from our team
A role for Afon Technology’s Glucowear
Afon Technology’s Glucowear is on the cusp of delivering that “Holy Grail” of monitoring systems, with accuracies comparable to the first-generation continuous glucose monitors.
Subscribe to our Newsletter
Subscribe to our Newsletter
Quick Links
Investments
Connect
Norcliffe Capital Ltd FRN # 826977 who is an Appointed Representative of Sturgeon Ventures LLP who is authorised and regulated by the Financial Conduct Authority FRN # 452811.
